Key result
Etomidate induction linked to ~44% higher 30-day mortality compared to propofol.
Why the study?
Etomidate is commonly used for anesthetic induction in hemodynamically unstable patients, but concerns persist regarding potential adverse outcomes including adrenal suppression and increased mortality compared with propofol.
Is intravenous anesthetic induction with etomidate independently associated with increased 30-day mortality and adverse postoperative outcomes compared to propofol in adult surgical patients?
Cohort (n=155,667)
Is intravenous anesthetic induction with etomidate independently associated with increased 30-day mortality and adverse postoperative outcomes compared to propofol in adult surgical patients?
Although etomidate reduces post-induction hypotension compared to propofol, its use for anesthetic induction is independently associated with higher 30-day mortality and postoperative cardiovascular, renal, and infectious complications.
Answers are grounded in this paper and cite their sources.
May warrant caution with etomidate induction; leaves open causality and need for randomized confirmation.
BACKGROUND: Etomidate is commonly used for induction in hemodynamically unstable patients to preserve cardiovascular stability. However, concerns persist regarding potential adverse outcomes, including adrenal suppression and increased mortality. We evaluated whether intravenous anesthetic induction with etomidate was independently associated with adverse postoperative outcomes as compared to propofol induction. METHODS: We conducted a retrospective cohort study of 155,667 adult surgical patients undergoing induction with etomidate or propofol at our academic health system. Patients younger than 18 years of age, those receiving preoperative mechanical ventilation, and those with American Society of Anesthesiologists physical status VI were excluded. The primary outcome was all-cause 30-day mortality; secondary outcomes included sepsis, acute coronary syndrome (ACS), cardiogenic shock, and acute kidney injury (AKI). Multivariable logistic regression adjusted for demographic, comorbidity, physiologic, and surgical factors. Given substantial baseline imbalance between induction groups, propensity score matching (1:1) using the same covariates was performed. Sensitivity analyses included adjustment for neutrophil-to-lymphocyte ratio, complete-case analyses, and interaction testing. RESULTS: A total of 155,667 patients met inclusion criteria, including 3846 (2.5%) who received etomidate and 151,821 (97.5%) who received propofol. Thirty-day mortality occurred in 1151 patients (0.74%). Unadjusted mortality was higher in the etomidate group (227/3846 [5.9%]) than in the propofol group (924/151,821 [0.61%]). After multivariable adjustment, etomidate use remained independently associated with increased 30-day mortality (aOR 1.44; 95% CI, 1.21–1.72; P < 0.001). Propensity score matching (n = 3832 per group) reduced the average standardized mean difference from 0.398 before matching to 0.023 after matching. The association persisted in the matched cohort (aOR 1.43; 95% CI, 1.14–1.78; P = 0.002), with observed mortality of 225/3832 (5.9%) among etomidate recipients and 157/3832 (4.1%) among propofol recipients, corresponding to an absolute risk difference of 1.8% and a number needed to harm of 56. In the matched cohort, etomidate was also associated with higher odds of sepsis (aOR 1.28; 95% CI, 1.08–1.52), acute coronary syndrome (aOR 1.24; 95% CI, 1.09–1.41), cardiogenic shock (aOR 1.56; 95% CI, 1.21–2.01), and acute kidney injury (aOR 1.27; 95% CI, 1.11–1.45). Post-induction hypotension was lower in the etomidate group (aOR 0.40, 95% CI 0.32–0.49; P < 0.001). Findings were consistent across sensitivity analyses. CONCLUSIONS: Etomidate induction was associated with increased 30-day mortality and major postoperative complications. Given the observational design, results should be interpreted with caution.
No takes yet. Share an insight, caveat, or question.
Kachhwaha et al. (2026) conducted a cohort in Adult surgical patients undergoing anesthetic induction (n=155,667). Etomidate vs. Propofol was evaluated on All-cause 30-day mortality (OR 1.44, 95% CI 1.21-1.72, p=<0.001). Etomidate induction was associated with higher 30-day mortality compared to propofol.
Synapse has enriched 10 related papers. Consider them for comparative context: